Increased serum asymmetric dimethylarginine level is an independent predictor of contrast-induced nephropathy

Turk Kardiyoloji Dernegi Arsivi

Volumn 41, Issue 7, 2013, Pages 581-588

  Günebakmaz, Özgür ^a   Duran, Mustafa ^b   Karakaya, Ekrem ^c   Tanrikulu, Esen ^c   Akpek, Mahmut ^c   Ergin, Ali ^c   Kaya, Mehmet Güngör ^c  

^a HARRAN UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b Kayseri Training and Research Hospital ^*  (Turkey)

^c ERCIYES UNIVERSITY   (Turkey)

Author keywords

Angina pectoris; Asymmetric dimethylarginine; Contrast media adverse effects; Coronary angiography; Creatinine blood

Indexed keywords

CREATININE; IOPROMIDE; N(G),N(G) DIMETHYLARGININE; SODIUM CHLORIDE; ARGININE; CONTRAST MEDIUM; N,N-DIMETHYLARGININE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ANGIOCARDIOGRAPHY; ARTICLE; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART VENTRICULOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEHRAN RISK SCORE; MIDDLE AGED; PREDICTION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; STABLE ANGINA PECTORIS; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ANGINA PECTORIS; BLOOD; CHEMICALLY INDUCED; KIDNEY DISEASE; PREDICTIVE VALUE; PROCEDURES; RADIOGRAPHY; RECEIVER OPERATING CHARACTERISTIC;

AGED; ANGINA PECTORIS; ARGININE; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CREATININE; FEMALE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; ROC CURVE;

EID: 84891849785     PISSN: 10165169     EISSN: None     Source Type: Journal    
DOI: 10.5543/tkda.2013.88403     Document Type: Article

References (39)

1. McCullough PA, Wolyn R, Rocher L.L., Levin RN, O'Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368-75.
2. Lindsay J, Apple S, Pinnow E.E., Gevorkian N., Gruberg L, Satler LF, et al Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine. Catheter Cardiovasc Interv 2003;59:338-43.
3. Mehran R, Aymong ED, Nikolsky E, Lasic Z., Iakovou I, Fahy M, et al A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004;44:1393-9.
4. Toprak O, Cirit M, Tanrisev M., Yazici C, Canoz O, Sipahiog-lu M, et al Preventive effect of nebivolol on contrast-induced nephropathy in rats. Nephrol Dial Transplant 2008;23:853-9.
5. Tumlin J, Stacul F, Adam A., Becker CR, Davidson C, La-meire N, et al Pathophysiology of contrast-induced nephropathy. Am J Cardiol 2006;98:14-20.
6. Conen D, Buerkle G, Perruchoud A.P., Buettner HJ, Mueller C. Hypertension is an independent risk factor for contrast nephropathy after percutaneous coronary intervention. Int J Cardiol 2006;110:237-41.
7. Gussenhoven MJ, Ravensbergen J, van Bockel JH, Feuth JD, Aarts JC Renal dysfunction after angiography; a risk factor analysis in patients with peripheral vascular disease. J Cardiovasc Surg (Torino). 1991;32:81-6.
8. Rihal CS, Textor SC, Grill D.E., Berger PB, Ting HH, Best PJ, et al Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:2259-64
9. Böger R.H., Bode-Böger SM. Asymmetric dimethylarginine, derangements of the endothelial nitric oxide synthase pathway, and cardiovascular diseases. Semin Thromb Hemost 2000;26:539-45.
10. Ngo DT, Sverdlov AL, McNeil J.J., Horowitz JD Correlates of arterial stiffness in an ageing population: role of asymmetric dimethylarginine. Pharmacol Res 2009;60:503-7.
11. Szuba A, Podgórski M. Asymmetric dimethylarginine (ADMA) a novel cardiovascular risk factor-evidence from epidemiological and prospective clinical trials. Pharmacol Rep 2006;58:16-20.
12. Toth J, Racz A, Kaminski P.M., Wolin MS, Bagi Z, Koller A. Asymmetrical dimethylarginine inhibits shear stress-induced nitric oxide release and dilation and elicits superoxide-medi-ated increase in arteriolar tone. Hypertension 2007;49:563-8.
13. Cockcroft DW, Gault MH Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
14. Nash K, Hafeez A, Hou S. Hospital-acquired renal insuffciency Am J Kidney Dis 2002;39:930-6.
15. Nikolsky E, Mehran R, Lasic Z., Mintz GS, Lansky AJ, Na Y, et al Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int 2005;67:706-13.
16. Ribeiro L, de Assunçãoe Silva F, Kurihara RS, Schor N, Mieko E, Higa S. Evaluation of the nitric oxide production in rat renal artery smooth muscle cells culture exposed to radiocontrast agents. Kidney Int 2004;65:589-96.
17. Sandhu C, Newman DJ, Morgan R, Belli A.M., Oliveira D. The role of oxygen free radicals in contrast induced nephrotoxicity. Acad Radiol 2002;9:436-7.
18. Goldenberg I, Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ 2005;172:1461-71.
19. Isenbarger DW, Kent SM, O'Malley PG Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. Am J Cardiol 2003;92:1454-8.
20. Koc F, Ozdemir K, Kaya M.G., Dogdu O., Vatankulu MA, Ayhan S, et al Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CA-SIS-a multicenter prospective controlled trial. Int J Cardiol 2012;155:418-23.
21. Patti G, Nusca A, Chello M., Pasceri V, D'Ambrosio A, Ve-trovec GW, et al Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol 2008;101:279-85.
22. Jo SH, Koo BK, Park J.S., Kang HJ, Cho YS, Kim YJ, et al Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insuffciency undergoing coronary angiography (PROMISS) trial-a randomized controlled study. Am Heart J 2008;155:499.e1-8.
23. Günebakmaz O., Kaya MG, Koc F, Akpek M., Kasapkara A, Inanc MT, et al Does nebivolol prevent contrast-induced nephropathy in humans? Clin Cardiol 2012;35:250-4.
24. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylaminohydro-lase pathway. Arterioscler Thromb Vasc Biol 2004;24:1023-30.
25. Böger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 2003;59:824-33.
26. Böger R.H., Maas R, Schulze F., Schwedhelm E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality-an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res 2009;60:481-7.
27. Schnabel R, Blankenberg S, Lubos E., Lackner KJ, Ruppre-cht HJ, Espinola-Klein C, et al Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005;97:e53-9.
28. Mittermayer F, Krzyzanowska K, Exner M., Mlekusch W, Amighi J, Sabeti S., et al Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol 2006;26:2536-40.
29. Anderssohn M, Schwedhelm E, Lüneburg N, Vasan R.S., Böger RH. Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitus. Diab Vasc Dis Res 2010;7:105-18.
30. Goonasekera CD, Rees DD, Woolard P, Frend A., Shah V, Dillon MJ Nitric oxide synthase inhibitors and hypertension in children and adolescents. J Hypertens 1997;15:901-9.
31. Leong T, Zylberstein D, Graham I., Lissner L, Ward D, Fog-arty J, et al Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-up of the population study of women in Gothenburg. Arterioscler Thromb Vasc Biol 2008;28:961-7.
32. Hedner T, Himmelmann A, Hansson L. Homocysteine and ADMA-emerging risk factors for cardiovascular disease? Blood Press 2002;11:197-200.
33. Jacobi J, Tsao PS Asymmetrical dimethylarginine in renal disease: limits of variation or variation limits? A systematic review. Am J Nephrol 2008;28:224-37.
34. Antoniades C, Shirodaria C, Leeson P., Antonopoulos A, Warrick N, Van-Assche T, et al Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. Eur Heart J 2009;30:1142-50.
35. Mihout F, Shweke N, Bigé N, Jouanneau C, Dussaule JC, Ronco P, et al. Asymmetric dimethylarginine (ADMA) induces chronic kidney disease through a mechanism involving collagen and TGF-b1 synthesis. J Pathol 2011;223:37-45.
36. Fliser D, Kronenberg F, Kielstein J.T., Morath C., Bode-Böger SM, Haller H, et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol 2005;16:2456-61.
37. Lajer M, Tarnow L, Jorsal A., Teerlink T, Parving HH, Rossing P Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2008;31:747-52.
38. Osthoff M, Piezzi V, Klima T., Christ A, Marana I, Hartwiger S., et al Impact of mannose-binding lectin defciency on ra-diocontrast-induced renal dysfunction: a post-hoc analysis of a multicenter randomized controlled trial. BMC Nephrol 2012;13:99.
39. McCullough PA, Williams FJ, Stivers D.N., Cannon L., Dixon S, Alexander P, et al Neutrophil gelatinase-associated lipocal-in: a novel marker of contrast nephropathy risk. Am J Nephrol 2012;35:509-14.